Sweden
· Delayed Price · Currency is SEK Coegin Pharma AB Company Description
Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer.
Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascular complications in diabetes; AVX420/FOL026 therapy in preclinical study for the treatment of kidney and liver fibrosis; and FOL005 for the treatment of stimulation of hair growth.
The company was founded in 2005 and is based in Lund, Sweden.
| Country | Sweden |
| Founded | 2005 |
| Industry | Pharmaceutical Preparations |
| Employees | 2 |
| CEO | Jens Eriksson |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 45 61 90 50 66 |
| Website | coeginpharma.com |
Stock Details
| Ticker Symbol | COEGIN |
| Exchange | Nasdaq Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jens Eriksson | Chief Executive Officer |
| Lars Rasmussen | Chief Financial Officer |